MSN laboratories launches posaconazole: this new launch is made to treat the new epidemic “Black fungus”


MSN Laboratories on Friday announced the launch of Posaconazole, a triazole antifungal agent indicated for treating Black Fungus (Mucormycosis) patients, in India.
According to a press release issued by the company, MSN has launched the product under the brand name PosaOne as 100 mg Delayed Release tablets and 300 mg injections, respectively.
“As an outcome of MSN’s competence in research and manufacturing of anti-fungal infection drugs, it is now targeting to pro-actively reach patients across India by ensuring the access of PosaOne, through its strong distribution network & field force,” the city-based drug maker said.
MSN has developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house Research and Development and manufacturing units.
The drug is approved by the Drug Controller General of India (DGCI) and matches the International quality standards. As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules and also licensed Baridoz (Baricitinib) recently with Eli Lilly.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close